In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS: Retaining Top Talent Through An Acquisition And A Pandemic

Executive Summary

Catherine Owen joined Bristol Myers Squibb in September 2019, tasked with overseeing the integration of Celgene and BMS’s international businesses. She talks to In Vivo about managing the merger of teams from two very distinct companies during a global pandemic. Owen, who is passionate about career growth and mentoring, also highlights the importance of talent development and sponsorship – even in times of uncertainty, when business as usual goes out the window. 

You may also be interested in...



In Vivo’s 2021 Rising Leaders: Recognizing Talent Across The Life Sciences

Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who is in the spotlight this year.

Putting Affordable Innovation Center Stage

Sarah Howell, one of In Vivo’s 2021 Rising Leaders, was appointed CEO of Arecor in 2015 and has led the company’s transformation into a successful clinical-stage biotechnology company. In an exclusive interview, Howell described Arecor as focused on “affordable innovation,” particularly in disease areas with large and growing patient populations, such as diabetes. 

30 Life Sciences Leaders To Watch In 2021

30 Rising Leaders who are making waves and challenging traditional structures across the biopharma and medtech sectors. In Vivo's 2021 list also includes industry stars that have raised their game in response to the COVID-19 pandemic. 

Topics

Related Companies

UsernamePublicRestriction

Register

IV124760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel